'Genetic polymorphisms' diaporamas de présentation

Introduction to pharmacogenomics and personalised medicine

1.74k views • 89 slides

Pharmacogenomics: Clinical Application and Effects on Drug Metabolism

Pharmacogenomics: Clinical Application and Effects on Drug Metabolism. Rodney J. Hunter, Pharm.D. Assistant Professor Texas Southern University College of Pharmacy and Health Sciences SNPhA Regional Conference District III, IV, & V February 19 th , 2011. Financial Disclosure.

880 views • 56 slides

RNAseq Applications in Genome Studies

RNAseq Applications in Genome Studies. Alexander Kanapin, PhD Wellcome Trust Centre for Human Genetics, University of Oxford. RNAseq Protocols. Next generation sequencing protocol cDNA, not RNA sequencing Types of libraries available: Total RNA sequencing polyA+ RNA sequencing

800 views • 37 slides

Pharmacogenomics Study in a Taiwan Methadone Maintenance Cohort

Pharmacogenomics Study in a Taiwan Methadone Maintenance Cohort. Dr. Yu-Li Liu National Health Research Institutes April 18, 2013. Acknowledgement. NHRI Dr. Ho, IK ( ??? ), Dr. Lin, KM ( ??? ), Dr. Wang, SC ( ??? )

559 views • 35 slides

Pediatric Drug Therapy

Pediatric Drug Therapy. Cortez,Anne ; Cortez,Feliza ; Cristi , Frances; Cruz,Denise ; Cruz,Ferdinand ; Cruz,Karen ; Cruz,Belle ; Cruz,Mary ; Cua,Ronald. Pharmacogenetics. Role of genetic factors in drug disposition and response

798 views • 34 slides

413 views • 26 slides

Computational Tools for Finding and Interpreting Genetic V a r i a t i o n s

161 views • 16 slides

FDA/CBER Role in Smallpox Vaccine Safety

FDA/CBER Role in Smallpox Vaccine Safety . Bob Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology CBER, FDA January 23, 2003. FDA/CBER Role in Smallpox Vaccine Safety. Office of Biostatistics and Epidemiology Vaccine Safety Branch VAERS Follow-up

268 views • 6 slides

Exclusion criteria (67) Patient cohort <100 (50) Re-analysis of same cohort (5) Off topic (12)

Studies on genetic polymorphisms in Hodgkin N=112. Exclusion criteria (67) Patient cohort <100 (50) Re-analysis of same cohort (5) Off topic (12). Unique studies selected for review N=45. Secondary malignancies/ toxicities N=3**. HLA susceptibility N=11. Non-HLA susceptibility N=19.

209 views • 1 slides